PF-Atlas › Clinical Trials › NCT00631475

Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443

Bosentan · Phase 3

Registry ID
NCT00631475
Phase
Phase 3
Status
Completed
Drug / intervention
Bosentan
Sponsor
Actelion
Start
2008-04
Enrollment
128

About this trial

This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).

View NCT00631475 on ClinicalTrials.gov →

Explore related

All Bosentan trialsAll IPF trials

Related trials

Bosentan — NCT00318175Bosentan — NCT00070590bosentan — NCT00625469bosentan — NCT01518595bosentan — NCT00071461Bosentan — NCT00637065
Medical disclaimer. This page summarizes public trial data for NCT00631475 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.